From the Guidelines
Fedratinib is not indicated for the treatment of infections. Fedratinib (brand name Inrebic) is a JAK2 inhibitor that is specifically approved for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, which is a bone marrow disorder. It works by inhibiting the Janus Associated Kinase 2 (JAK2) pathway, which is often dysregulated in myeloproliferative neoplasms. The provided evidence does not directly discuss the role of Fedratinib in treating infections, but rather focuses on the risk of infection associated with other targeted drugs, such as gilteritinib, as reported in a study published in the journal Leukemia 1. Key points to consider when evaluating the use of Fedratinib include:
- Fedratinib has no direct antimicrobial properties and should not be used to treat bacterial, viral, fungal, or parasitic infections.
- Patients taking fedratinib may have an increased risk of developing infections due to its immunosuppressive effects.
- The typical dosage for its approved indication is 400 mg orally once daily, but this is only relevant for myelofibrosis treatment. If you are dealing with an infection, appropriate antimicrobial agents should be selected based on the type of infection, suspected pathogens, and antimicrobial susceptibility testing when available. Consult with a healthcare provider for proper infection management, as they can provide guidance on the best course of treatment based on the specific circumstances of the infection.
From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Role of Fedratinib in Treating Infections
- There is no evidence to suggest that Fedratinib (Tivaritinib) is used to treat infections.
- The provided studies 2, 3, 4, 5, 6 focus on the use of Fedratinib in treating myeloproliferative neoplasm-associated myelofibrosis, a type of blood cancer.
Fedratinib's Mechanism of Action
- Fedratinib is a selective JAK2 inhibitor, which means it targets the JAK2 enzyme to reduce cell proliferation and inhibit the progression of myelofibrosis 3, 4, 6.
- It has also been shown to have inhibitory effects on other kinases, such as FLT3 and BRD4 4.
Clinical Use of Fedratinib
- Fedratinib is approved for the treatment of adult patients with intermediate-2 or high-risk myelofibrosis, regardless of prior JAK inhibitor treatment 3, 5, 6.
- It is often used in the second-line setting after intolerance or resistance to other JAK inhibitors, but can also be used as a first-line option in certain patient populations 4, 5.